Fundz

ZhiTai Bio Raises Over RMB 500M in Series C Funding, Led by OrbiMed, to Enhance Clinical Development of Long-Acting Weight Loss Drugs.

PRIVATEMar 02, 2026

Amount Raised

¥500 Million

Round Type

Series C

BiotechnologyHealth CarePharmaceutical

Investors

BlueRun VenturesOrbimedTaiyu InvestmentTaifu CapitalHuagai CapitalQiming Venture PartnersWuyuan CapitalXingze Capital

Description

ZhiTai Bio has secured over 500 million RMB in Series C financing, with OrbiMed leading the round. Other prominent investors include Qiming Venture Partners and Wuyuan Capital. The funding will support the company's efforts in developing innovative weight loss drugs. ZhiTai Bio focuses on technology that offers better patient compliance and improved treatment outcomes.

Who else raised in Pharmaceutical and Biotechnology around the same time

Companies in the same sectors as ZhiTai Bio that raised within 45 days of this round, from Fundz verified event records.

  • Turn Therapeutics Inc. raised $25M (Debt Financing) on March 24, 2026.
  • Cnbx Pharmaceuticals raised $45K (Debt Financing) on March 10, 2026.
  • Os Therapies raised $2M on March 4, 2026.
  • Botanix Pharmaceuticals raised $33M (Funding Round) on February 17, 2026.
  • Nasus Pharma raised $15M on February 10, 2026.
  • STORM Therapeutics raised $56M (Series C) on April 16, 2026.

Who to call at ZhiTai Bio, and when

A new round usually means ZhiTai Bio is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day ZhiTai Bio raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at ZhiTai Bio, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at ZhiTai Bio. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

ZhiTai Bio

About

ZhiTai Bio, founded in 2018, specializes in the development of recombinant protein drugs for chronic metabolic diseases. The company is focused on innovative long-acting, oral peptides, and multi-target drugs, particularly in the area of weight loss. Its pipeline includes Zoweiglutide, a long-acting peptide GLP-1RA injection undergoing Phase III clinical trials, along with other candidates targeting various metabolic disorders.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment ZhiTai Bio raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Predictive Intelligence
Strategic

ML-powered predictions for ZhiTai Bio's next move

See what Strategic adds

ZhiTai Bio raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.